Syndax Pharmaceutica
SNDX
Delayed Nasdaq - 01/18 10:00:00 pm
9.58USD
+4.81%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 20162017
Sales1,222,64
EBITDA--62,5
Operating profit (EBIT)-43,8-60,3
Pre-Tax Profit (EBT)-44,1-59,6
Net income-44,1-58,9
EPS ( $ )-3,22-2,84
Dividend per Share ( $ )--
Yield--
Announcement Date03/02/2017
09:05pm
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 20162017
Debt--
Finance-140
Operating income (EBITDA)--62,5
Leverage
(Debt/EBITDA)
--
Capital Expenditure0,260,37
Book Value Per Share (BVPS)-3,75 $
Cash Flow per Share--
Announcement Date03/02/2017
09:05pm
-
Balance Sheet Analysis
Financial Ratios
Size 2017e 2018e
Capitalization 223 M$ -
Entreprise Value (EV) 82,7 M$ 69,3 M$
Valuation 2017e 2018e
P/E ratio (Price / EPS)
Capitalization / Revenue 84,4x 214x
EV / Revenue 31,3x 66,7x
EV / EBITDA -1,32x -0,97x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 2,44x 1,86x
Profitability 2017e 2018e
Operating Margin (EBIT / Sales) -2 286% -7 745%
operating Leverage (Delta EBIT / Delta Sales) - -0,55x
Net Margin (Net Profit / Revenue) -2 232% -7 779%
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) -74,7% -65,6%
Rate of Dividend - -
Balance Sheet Analysis 2017e 2018e
CAPEX / CA   13,9% 39,6%
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) 2,25x 2,15x
BNA & Dividende